3月31日,礼来制药宣布:lepodisiran第二阶段临床试验结果偏正面,实现主要终点。lepodisiran在以最高测试剂量 (400毫克) 治疗后,在60至180天内显著降低了Lp(a)水平,平均降低了93.9%,达到了主要终点。Lepodisiran是一种与N-乙酰半乳糖胺结合的LPA-特异性siRNA,可降解肝脏LPA mRNA,从而降低循环Lp(a)水平。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.